Child Antipsychotic Users Face Early Metabolic Risk

Hong Kong records show metabolic abnormalities rising sharply in the first weeks of treatment for children aged 6 to 17.

Updated on Nov. 5, 2026 in Children’s Health

Child Antipsychotic Users Face Early Metabolic Risk

Children prescribed antipsychotic medications showed sharply elevated rates of metabolic problems, particularly high cholesterol, in the first weeks after starting treatment, according to a study of Hong Kong public healthcare records. The findings were published October 28 in JAMA Network Open and are most relevant to families and clinicians of children aged 6 to 17 who are prescribed these drugs.

Why it matters

Metabolic side effects such as blood sugar and lipid changes raise longer-term cardiovascular and diabetes risk, so understanding when they emerge helps shape monitoring. The study's detailed timeline shows that the highest-risk window is the first days to weeks of treatment, which is when early laboratory checks may matter most.

This retrospective cohort study drew on Hong Kong public healthcare records for 15,219 children aged 6 to 17 who began antipsychotic treatment, tracked over 18 years from 2005. Among the 497 patients who developed metabolic abnormalities, about 90% had dyslipidemia and about 23% had hyperglycemia, with incidence rate ratios compared against a baseline period.

The players

JAMA Network Open

A peer-reviewed open-access medical journal published by the American Medical Association that covers clinical research across many specialties.

University of Hong Kong

A leading research university whose medical faculty conducts clinical and public health research, including studies using Hong Kong's public healthcare data.

The details

The analysis divided each child's observation time into baseline, pre-exposure, first-episode exposure, subsequent exposure, and postexposure periods, allowing researchers to compare risk before and after treatment began. Primary outcomes included the earliest occurrence of high blood sugar or abnormal lipids, medication treatment for those conditions, or abnormal laboratory results. Dyslipidemia, which refers to abnormal fat levels in the blood, dominated the findings and was most pronounced in the first week. The risk pattern was time-dependent, with incidence rate ratios climbing from the first month into the following three months.

Timeline

  1. 2005: Start of the 18-year public healthcare records analysis period

  2. Days 0-7 after treatment starts: dyslipidemia risk peaks at about 62 times baseline

  3. Days 8-30 after treatment starts: metabolic abnormality rate is about 5.6 times baseline

  4. Days 31-90 after treatment starts: metabolic abnormality rate rises to about 7.7 times baseline

  5. October 28, 2026: Study published online in JAMA Network Open

Health Landscape

Antipsychotics are used in children for conditions including severe behavioral and psychiatric disorders, and metabolic side effects have long been a monitoring concern in this population. This Hong Kong cohort adds a detailed time-course showing that metabolic risk concentrates early, which sharpens the question of how monitoring schedules should be set across health systems worldwide.

If your child has been prescribed an antipsychotic, the study suggests the first weeks of treatment are when metabolic changes appear most quickly, so it is worth asking the prescriber whether blood sugar and cholesterol checks are scheduled early. Do not change or stop any medication based on this study; discuss monitoring questions with your child's doctor.

The takeaway

Metabolic changes in children on antipsychotics appear to concentrate in the first weeks of treatment, which supports early laboratory monitoring. Parents and caregivers should ask their child's clinician about the scheduled blood sugar and cholesterol checks and what the monitoring plan looks like.

Further reading

For more on how childhood conditions and treatments are tracked over time, explore our Children's Health coverage.

Source note: This article includes information reported by Medscape.